Adriamycin-induced Heart Failure: Mechanism and Modulation

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2000 Jul 11

PMID 10888230

Citations 118

Authors

P K Singal

T Li

D Kumar

I Danelisen

N Iliskovic

Affiliations

Soon will be listed here.

Abstract

Adriamycin (doxorubicin) is one of the most effective chemotherapeutic agents against a variety of cancers, but its usefulness is seriously curtailed by the risk of developing heart failure. Available laboratory evidence suggests that an increase in oxidative stress, brought about by increased free radical production and decreased myocardial endogenous antioxidants, plays an important role in the pathogenesis of heart failure. Adriamycin-induced apoptosis and hyperlipidemia may also be involved in the process. Probucol, a lipid-lowering drug and an antioxidant, completely prevents the occurrence of heart failure by reducing oxidative stress as well as by the modulation of apoptosis and high lipid concentrations. Thus, combined therapy with adriamycin and probucol has a high potential for optimizing the treatment of cancer patients.

Citing Articles

Metformin Alleviates Doxorubicin-Induced Cardiotoxicity via Preserving Mitochondrial Dynamics Balance and Calcium Homeostasis.

Maghraby N, El-Baz M, Hassan A, Abd-Elghaffar S, Ahmed A, Sabra M Appl Biochem Biotechnol. 2025; .

PMID: 39792339 DOI: 10.1007/s12010-024-05141-9.

Melatonin mitigates doxorubicin induced chemo brain in a rat model in a NRF2/p53-SIRT1 dependent pathway.

Ebrahim N, Elnagar M, El-Gamal R, Habotta O, Albadawi E, Albadrani M Heliyon. 2024; 10(19):e38081.

PMID: 39386846 PMC: 11462207. DOI: 10.1016/j.heliyon.2024.e38081.

Nanomedicine And Nanotheranostics: Special Focus on Imaging of Anticancer Drugs Induced Cardiac Toxicity.

Setia A, Challa R, Vallamkonda B, Satti P, Mehata A, Priya V Nanotheranostics. 2024; 8(4):473-496.

PMID: 38961885 PMC: 11217786. DOI: 10.7150/ntno.96846.

Cardioprotective Potential of Leaf Extract Loaded Niosomes Nanoparticles - Against Doxorubicin Toxicity In Rats.

Mohamad E, Ahmed S, Masoud M, Mohamed F, Mohammed H Curr Pharm Biotechnol. 2024; 26(2):289-301.

PMID: 38918977 DOI: 10.2174/0113892010303097240605105013.

Effect of Pyridoxine Derivative B6NO on Transcription Factor Nrf2 Activity and Cytotoxic Properties of Doxorubicin In Vitro.

Balakina A, Amozova V, Prikhodchenko T, Stupina T, Mishchenko D Bull Exp Biol Med. 2024; 176(5):687-696.

PMID: 38733479 DOI: 10.1007/s10517-024-06091-2.

References

Doroshow J . Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 1983; 43(2):460-72. View

Hiramatsu M, Liu J, Edamatsu R, Ohba S, Kadowaki D, Mori A . Probucol scavenged 1,1-diphenyl-2-picrylhydrazyl radicals and inhibited formation of thiobarbituric acid reactive substances. Free Radic Biol Med. 1994; 16(2):201-6. DOI: 10.1016/0891-5849(94)90144-9. View

Di Marco A, Gaetani M, SCARPINATO B . Adriamycin (NSC-123,127): a new antibiotic with antitumor activity. Cancer Chemother Rep. 1969; 53(1):33-7. View

Booser D, Hortobagyi G . Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs. 1994; 47(2):223-58. DOI: 10.2165/00003495-199447020-00002. View

Von Hoff D, Layard M, Basa P, Davis Jr H, Von Hoff A, Rozencweig M . Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91(5):710-7. DOI: 10.7326/0003-4819-91-5-710. View

Seifert C, Nesser M, Thompson D . Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother. 1994; 28(9):1063-72. DOI: 10.1177/106002809402800912. View

Olson R, Macdonald J, vanBoxtel C, BOERTH R, Harbison R, Slonim A . Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of adriamycin. J Pharmacol Exp Ther. 1980; 215(2):450-4. View

Young R, Ozols R, Myers C . The anthracycline antineoplastic drugs. N Engl J Med. 1981; 305(3):139-53. DOI: 10.1056/NEJM198107163050305. View

Doroshow J, Locker G, Baldinger J, Myers C . The effect of doxorubicin on hepatic and cardiac glutathione. Res Commun Chem Pathol Pharmacol. 1979; 26(2):285-95. View

10.

Yokoi H, Daida H, Kuwabara Y, Nishikawa H, Takatsu F, Tomihara H . Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol. 1997; 30(4):855-62. DOI: 10.1016/s0735-1097(97)00270-2. View

11.

Sharov V, Sabbah H, Shimoyama H, Goussev A, Lesch M, Goldstein S . Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol. 1996; 148(1):141-9. PMC: 1861595. View

12.

Speyer J, Green M, Zeleniuch-Jacquotte A, Wernz J, Rey M, Sanger J . ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992; 10(1):117-27. DOI: 10.1200/JCO.1992.10.1.117. View

13.

Jackson J, Reeves J, Muntz K, Kruk D, Prough R, Willerson J . Evaluation of free radical effects and catecholamine alterations in adriamycin cardiotoxicity. Am J Pathol. 1984; 117(1):140-53. PMC: 1900556. View

14.

Oliver M, Kurien V, Greenwood T . Relation between serum-free-fatty acids and arrhythmias and death after acute myocardial infarction. Lancet. 1968; 1(7545):710-4. DOI: 10.1016/s0140-6736(68)92163-6. View

15.

Singal P, Pierce G . Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol. 1986; 250(3 Pt 2):H419-25. DOI: 10.1152/ajpheart.1986.250.3.H419. View

16.

BARNHART J, Sefranka J, McIntosh D . Hypocholesterolemic effect of 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (probucol). Am J Clin Nutr. 1970; 23(9):1229-33. DOI: 10.1093/ajcn/23.9.1229. View

17.

Mettler F, Young D, Ward J . Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats. Cancer Res. 1977; 37(8 Pt 1):2705-13. View

18.

Tong J, Ganguly P, Singal P . Myocardial adrenergic changes at two stages of heart failure due to adriamycin treatment in rats. Am J Physiol. 1991; 260(3 Pt 2):H909-16. DOI: 10.1152/ajpheart.1991.260.3.H909. View

19.

Singal P, Segstro R, Singh R, Kutryk M . Changes in lysosomal morphology and enzyme activities during the development of adriamycin-induced cardiomyopathy. Can J Cardiol. 1985; 1(2):139-47. View

20.

Doroshow J, Locker G, Myers C . Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest. 1980; 65(1):128-35. PMC: 371347. DOI: 10.1172/JCI109642. View